What it sells
Bioengineered kidneys for patients with kidney failure
Business model breakdown
Workflow: what inputs become what output?
Developing a stem cell-based bioengineered kidney therapy combining stem cell biology, biofabrication, fluidics and cell manufacturing.
Economics: what it saves and how it charges
Pre-commercial; funded by prizes and collaborations, e.g. $1M KidneyX Artificial Kidney Prize (2023) and a 2025 research collaboration with Humacyte.
Funding history and coverage
| Round date | Stage | Amount | Investors | Source |
|---|---|---|---|---|
| — | Y Combinator Winter 2021 | — | Y Combinator | ycombinator.com |
Profiles summarize public reporting and company websites. Business-model notes are MaxBC's reading of that material, not confirmed facts; unknowns are left blank rather than guessed. Updated 2026-10-12.